This refresh
Data-driven refresh October 5, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,244 tickers); 1,692 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top 30 — quality compounders at a fair price
1. ADBE — Adobe Inc. · score 88.6
Software - Application · price $238.78 · 1Y $275.06 · 5Y $402.72 · 10Y $597.41
FCF $10.6b A- · Rev +12.0% B+ · D/E 0.58 C+ · P/E 13.3x A- · PEG 0.57 A-
Why now. Adobe’s Digital Media suite—Photoshop, Premiere and the Creative Cloud—continues to dominate the creator economy, fueling a 12% revenue growth YoY while delivering a 28% profit margin and a massive ROE of 61.9%. The Bull Rankings model scores Quality at 92, the highest pillar, reflecting this cash‑generating efficiency, and the stock trades at a Value score of 87, meaning it’s cheap relative to peers. With the market pricing only a -2% FCF growth start versus the actual 12% top‑line expansion, the upside is baked in, making the current price a bargain for a business that can sustain its creator‑centric moat.
Moat. Adobe’s moat lies in the sticky, subscription‑based Creative Cloud platform that locks in photographers, video editors, designers and marketers, creating high switching costs and a network effect as assets are stored and shared across the Adobe ecosystem. The 61.9% ROE stems from pricing power in this category‑leadership position, allowing Adobe to monetize upgrades and add‑on services without significant cost escalation.
Risk. The biggest headwind is the high beta of 1.42 and a P/E of 13.3 that, while modest, still reflects market expectations of slowing growth; the reverse‑DCF shows a negative FCF growth rate of -2% in year 1, signaling that any deceleration below the 12% revenue pace could compress margins and erode returns. A sustained slowdown in Digital Media subscriptions or a successful challenger platform would validate this risk and break the bull case.
Horizon. 1-3 yr $275.06 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $402.72 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $597.41 if current growth sustains into durable earnings power.
2. FICO — Fair Isaac Corporation · score 87.4
Software - Application · price $689.61 · 1Y $1,207 · 5Y $1,767 · 10Y $2,622
FCF $996m C+ · Rev +24.1% A- · D/E Negative equity · P/E 20.0x B+ · PEG 0.58 A-
Why now. FICO’s Scores segment is entrenched in the credit‑decision workflow of banks and fintechs, feeding predictive credit scores directly into transaction streams. That moat fuels a 24.1% revenue growth, a 34.1% profit margin, and $996 m of free cash flow, all while trading at a modest PEG of 0.58. The thesis rests on the relentless compounding of scoring demand as digital lending expands, making the current price a launchpad for outsized upside.
Moat. The Scores business locks customers into long‑term contracts because credit‑scoring models are deeply embedded in underwriting systems, creating high switching costs and a data‑network advantage that rivals can’t replicate quickly. MyFICO’s consumer subscription adds a sticky, recurring‑revenue layer, while the Software segment’s pre‑configured decision‑management suites deepen integration across account origination and customer‑management processes.
Risk. FICO’s negative ROE of ‑19.9% signals that earnings are being eroded by share‑count dilution and capital allocation choices, while a beta of 1.34 amplifies market swings. The Bull Rankings model’s reverse‑DCF assumes free‑cash‑flow growth starting at 10%, well below the 24.1% trailing revenue growth, implying the market is already pricing in slower growth; any further deceleration would crush the upside. A breach of the 52‑week low ($586.05) would confirm the bear case.
Horizon. 1-3 yr $1,207 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $1,767 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $2,622 if current growth sustains into durable earnings power.
3. HRMY — Harmony Biosciences Holdings, Inc. · score 87.2
Biotechnology · price $39.92 · 1Y $47.64 · 5Y $69.74 · 10Y $103.46
FCF $355m C · Rev +24.3% A- · D/E 0.16 B+ · P/E 12.9x A- · PEG 0.38 A
Why now. HRMY’s growth engine is anchored by WAKIX, the only FDA‑approved pitolisant therapy for narcolepsy, which fuels a 24.3% revenue growth and a 18.9% profit margin. Our Bull Rankings model flags a top‑scoring Growth pillar (91) and a cheap Value rating (91), meaning the market is already discounting the business relative to peers. With a PE of 12.9 and a PEG of 0.38, the stock trades at a deep discount to its earnings growth, making the upside hinge on expanding WAKIX’s market share and advancing the Phase‑3 PWS trial.
Moat. WAKIX’s novel histamine‑H3 antagonism gives HRMY a protected niche in the rare‑neurology space, backed by exclusive U.S. patents that prevent generic entry for years. The therapy’s demonstrated efficacy creates high switching costs for patients and neurologists, while the company’s commercial infrastructure in specialty pharmacies locks in repeat prescriptions, translating the 18.1% ROE into pricing power from category leadership.
Risk. The Bull Rankings model’s reverse‑DCF shows a starting free‑cash‑flow decline of –15% YoY, far below the 24.3% revenue growth, implying cash‑flow pressure if new indications stumble. A single Phase‑2/3 failure in the Myotonic Dystrophy or Prader‑Willi pipelines would crush growth expectations, and the stock’s beta of 1.01 means market volatility will amplify any disappointment. Confirmation of the bear case would be a missed endpoint in the upcoming PWS trial, triggering a sharp re‑rating.
Horizon. 1-3 yr $47.64 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $69.74 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $103.46 if current growth sustains into durable earnings power.
4. NBIX — Neurocrine Biosciences, Inc. · score 87.1
Drug Manufacturers - Specialty & Generic · price $144.21 · 1Y $207.81 · 5Y $304.26 · 10Y $451.34
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 21.1x B+ · PEG 0.29 A
Why now. Drug Manufacturers - Specialty & Generic · market cap $14.7b. Down 23% from 52-week high of $186.12 — deep drawdown territory. Revenue growing +34% — in hypergrowth territory. PEG 0.29 — paying under fair value for the growth rate. 29 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $207.81 (implying +44% upside).
Moat. Net margin 21% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 19% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 123% of net income — earnings translate cleanly into cash.
Risk. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon. 1-3 yr $207.81 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $304.26 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $451.34 if current growth sustains into durable earnings power.
5. DLO — DLocal Limited · score 86.4
Software - Infrastructure · price $14.52 · 1Y $18.80 · 5Y $23.73 · 10Y $30.44
FCF $413m C · Rev +46.6% A · D/E 0.12 B+ · P/E 21.4x B+ · PEG 0.62 A-
Why now. Software - Infrastructure · market cap $4.3b. 13% off the 52-week high of $16.78. Revenue growing +47% — in hypergrowth territory. PEG 0.62 — paying under fair value for the growth rate. 10 sell-side analysts publish a mean 1-yr target of $18.80 (implying +29% upside).
Moat. Net margin 18% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Free cash flow runs well ahead of reported net income, mostly because of cash released from working capital ($165m) — a release that doesn't repeat every year the way earnings can.
Risk. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $18.80 (analyst consensus (n=10)) — multiple re-rating thesis requires a catalyst. 5 yr $23.73 at ~10% CAGR — dividend compounding plus earnings growth. 10 yr $30.44 if the moat survives secular pressure.
6. NVDA — NVIDIA Corporation · score 85.7
Semiconductors · price $238.90 · 1Y $328.72 · 5Y $481.27 · 10Y $713.94
FCF $127.0b A · Rev +83.4% A · D/E 0.17 B+ · P/E 30.2x B · PEG 0.29 A
Why now. NVIDIA’s AI‑driven data‑center compute platform is the engine of its explosive growth, delivering 83.4% revenue growth YoY while preserving a 63.7% profit margin and generating $127.0 billion of free cash flow. The Bull Rankings model flags Growth as the strongest pillar (100), meaning the business is compounding at a rate few peers can match, and the 1‑yr consensus target of $328.72 reflects that momentum. The thesis rests on the continuation of AI‑centric demand that fuels this compounding engine.
Moat. The Compute & Networking segment locks in customers with custom AI accelerators and networking stacks that are hard‑to‑replace, creating massive switching costs for hyperscale cloud providers. NVIDIA’s ROE of 84.2% stems from pricing power in a market where its GPUs are the de‑facto standard for AI workloads, a position competitors cannot duplicate quickly due to the company’s extensive IP portfolio and software ecosystem.
Risk. A 2.22 beta and a forward P/E of 30.2 signal that the stock is already priced for rapid growth; the reverse DCF assumes a 49% FCF growth rate in year 1, well below the trailing 83.4% revenue surge, implying the market is betting on a sharp slowdown. If AI spend contracts or data‑center capex stalls, the high valuation could crumble, and a breach of the 52‑week low at $164.27 would confirm the bear case.
Horizon. 1-3 yr $328.72 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $481.27 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $713.94 if current growth sustains into durable earnings power.
7. WIX — Wix.com Ltd. · score 85.7
Software - Infrastructure · price $74.06 · 1Y $79.65 · 5Y $116.62 · 10Y $172.99
FCF $564m C+ · Rev +13.2% B+ · D/E Negative equity · P/S 1.6x A- · PEG 0.15 A
Why now. Wix.com’s rapid adoption of Wix Studio and Velo by Wix is fueling a sustainable revenue engine, as evidenced by 13.2% YoY revenue growth, a robust $564 m free‑cash‑flow run‑rate, and an ultra‑low PEG of 0.15 that signals deep undervaluation. The consensus 1‑yr target of $79.65 already prices in modest upside, but the real catalyst is the compounding power of its no‑code/low‑code platform expanding into higher‑margin enterprise sites, which should keep growth compounding for years to come.
Moat. The unified Wix Studio environment locks users into a single, drag‑and‑drop workflow while the Velo developer stack lets them build custom web apps without code, creating high switching costs. Combined with the Wix App Market’s ecosystem of paid extensions, this network effect makes it costly for creators to migrate to rivals, preserving margin upside and user stickiness.
Risk. Wix’s profitability is fragile – a meager 2.5% profit margin and a negative ROE of -13.8% reveal cash‑burning pressure, and the reverse‑DCF shows the market assumes a starting free‑cash‑flow decline of -19% YoY, well below the 13.2% revenue growth delivered. If the platform’s growth stalls or margins compress further, the stock could slide toward its 52‑week low of $40.16, confirming the bear case.
Horizon. 1-3 yr $79.65 (analyst consensus (n=20)) — fundamentals + valuation re-rating. 5 yr $116.62 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $172.99 if current growth sustains into durable earnings power.
8. APP — AppLovin Corporation · score 84.8
Advertising Agencies · price $281.97 · 1Y $497.05 · 5Y $727.72 · 10Y $1,080
FCF $4.5b B · Rev +60.6% A · D/E 1.11 C+ · P/E 21.7x B · PEG 0.58 A-
Why now. The bull case hinges on MAX, AppLovin’s AI‑driven in‑app bidding platform, which is scaling publisher inventory value at breakneck speed. The business just delivered 60.6% revenue growth YoY, translates into a 64.6% profit margin and generated $4.5 B of free cash flow – a rare cash‑rich growth engine. Our Bull Rankings model flags a Growth pillar of 96, meaning the compounding engine is still roaring, while the reverse‑DCF shows the market only assumes a 26% FCF growth start‑point, well below the 60% top‑line pace, leaving ample upside.
Moat. MAX creates a two‑sided network: publishers lock in higher yields from real‑time auctions, and developers depend on the platform’s AI optimization to monetize every impression. This switching cost, reinforced by Adjust’s analytics lock‑in, makes it costly for rivals to poach AppLovin’s high‑value inventory, preserving margin and cash flow durability.
Risk. The bear case centers on valuation and volatility – a P/E of 21.7 is lofty for an advertising name, and a beta of 2.56 signals sharp price swings. Moreover, the reverse‑DCF’s implied 26% FCF growth is already a downgrade from the 60% revenue surge, suggesting the market expects a steep deceleration. A sustained slowdown or a spike in debt‑to‑equity (currently 1.11) would crush the upside.
Horizon. 1-3 yr $497.05 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $727.72 at ~21% CAGR — compounding case rests on the competitive position widening. 10 yr $1,080 if current growth sustains into durable earnings power.
9. PGY — Pagaya Technologies Ltd. · score 84.3
Software - Infrastructure · price $18.40 · 1Y $28.91 · 5Y $42.33 · 10Y $62.79
FCF $252m C · Rev +25.6% A- · D/E 1.34 C · P/E 13.3x A- · PEG 0.03 A
Why now. Pagaya’s Decline Monetization engine is unlocking a hidden pool of creditworthy borrowers, driving a 25.6% YoY revenue surge while the business trades at a modest PE of 13.3x and delivers a solid ROE of 19.5%. The Bull Rankings model scores a 93 on Value, confirming the stock is cheap relative to peers, and the 92‑point Growth pillar shows the revenue runway will keep compounding. The thesis hinges on scaling Decline Monetization across more U.S. lenders, which should sustain high‑single‑digit earnings growth for years to come.
Moat. The Decline Monetization platform creates a sticky data‑driven network: once a partner integrates Pagaya’s AI‑powered loan‑approval loop, switching costs rise because the partner’s underwriting models become calibrated to Pagaya’s proprietary risk signals. This lock‑in, combined with the company’s 19.5% ROE, stems from pricing power in a niche where few rivals have comparable AI infrastructure and access to the same institutional investor pool.
Risk. A 5‑year beta of 5.52 signals extreme market sensitivity, and the model flags “Diluting shareholders” – the company’s 1.34 debt‑to‑equity ratio could balloon if it raises capital to fund growth, eroding returns. Moreover, the reverse‑DCF shows implied free‑cash‑flow growth of –7% in year 1, far below the 25.6% revenue growth, suggesting the market already discounts future cash generation. A sustained rise in financing costs or a miss on scaling Decline Monetization would confirm the bear case and crush the upside.
Horizon. 1-3 yr $28.91 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $42.33 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $62.79 if current growth sustains into durable earnings power.
10. CARG — CarGurus, Inc. · score 82.5
Internet Content & Information · price $29.35 · 1Y $42.00 · 5Y $61.49 · 10Y $91.22
FCF $315m C · Rev +13.9% B+ · D/E 0.70 B · P/E 15.6x B · PEG 0.65 A-
Why now. CarGurus’ Digital Deal platform is turning its massive shopper‑dealer network into a high‑margin, recurring revenue engine, fueling a 13.9% revenue growth run‑rate and an 18.2% profit margin. The Bull Rankings model rates the business’s Quality at 86, underscoring the durability of its dealer subscription fees and advertising moat, while a PE of 15.6x signals reasonable valuation relative to peers. The thesis rests on the continuation of this compounding growth, which the model’s strongest pillar (Quality) tells us is already baked into the price.
Moat. The platform’s integrated suite—dealer subscriptions, manufacturer advertising, and the Digital Deal checkout—creates a two‑sided network that locks dealers in with predictable revenue and gives shoppers a frictionless buying experience. This scale translates into a ROE of 66.6%, driven by pricing power that competitors can’t replicate without building a comparable dealer base.
Risk. The reverse‑DCF shows the market pricing in a negative -7% free‑cash‑flow growth in year 1, far below the actual 13.9% revenue growth, implying pessimism that could be validated if growth stalls or margins compress. A beta of 1.22 and a debt‑to‑equity of 0.7 add volatility risk, and a pull‑back in dealer spend would quickly erode the high ROE. A sustained slowdown would confirm the bear case.
Horizon. 1-3 yr $42.00 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $61.49 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $91.22 if current growth sustains into durable earnings power.
11. DECK — Deckers Outdoor Corporation · score 82.1
Footwear & Accessories · price $80.21 · 1Y $120.41 · 5Y $176.29 · 10Y $261.52
FCF $1.1b C+ · Rev +9.8% B · D/E 0.21 A- · P/E 11.3x A- · PEG 0.97 B+
Why now. Deckers' HOKA performance‑footwear franchise is accelerating premium demand in the high‑growth running and trail segment, driving revenue up 9.8% YoY while preserving a robust 18.4% profit margin and delivering a stellar 42.6% ROE. Coupled with a low PE of 11.3 and a buy‑back program, the stock is positioned to capture the upside of continued brand‑led pricing power. The thesis rests on the persistence of HOKA’s momentum and the ability to translate that into compounding earnings.
Moat. Deckers leverages the HOKA and UGG brands to command pricing power in the premium lifestyle and performance footwear categories, a dynamic that fuels its 42.6% ROE by extracting higher margins from loyal consumers who are unwilling to switch to lower‑priced alternatives. Its direct‑to‑retail and global distributor network further entrenches the brands, making substitution costly and rapid copycat entry difficult.
Risk. The Bull Rankings model flags that the reverse‑DCF assumes a starting free‑cash‑flow contraction of –4% versus the 9.8% revenue growth just delivered, implying the market is pricing in a sharp slowdown; a sustained miss on HOKA’s growth could push the stock toward its 52‑week low of $77.20. Additionally, a beta of 1.12 amplifies market volatility, and any earnings miss would quickly erode the modest valuation cushion.
Horizon. 1-3 yr $120.41 (analyst consensus (n=22)) — fundamentals + valuation re-rating. 5 yr $176.29 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $261.52 if current growth sustains into durable earnings power.
12. DOCS — Doximity, Inc. · score 82
Health Information Services · price $28.58 · 1Y $29.67 · 5Y $43.43 · 10Y $64.43
FCF $306m C · Rev +11.2% B · D/E 0.01 A- · P/E 33.6x C+ · PEG 0.59 A-
Why now. Health Information Services · market cap $5.1b. Down 61% from 52-week high of $73.92 — deep drawdown territory. Revenue growing +11%, comfortably above the S&P median. PEG 0.59 — paying under fair value for the growth rate. 18 sell-side analysts rate this a Hold with a mean 1-yr target of $29.67 (implying +4% upside).
Moat. Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 18% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 183% of net income — earnings translate cleanly into cash.
Risk. Down 61% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 34x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon. 1-3 yr $29.67 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $43.43 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $64.43 if current growth sustains into durable earnings power.
13. EXLS — ExlService Holdings, Inc. · score 81.8
Information Technology Services · price $35.90 · 1Y $44.63 · 5Y $65.34 · 10Y $96.92
FCF $297m C · Rev +13.4% B+ · D/E 0.57 C+ · P/E 22.7x B+ · PEG 0.93 B+
Why now. EXLS’s AI‑powered claims and underwriting platform in the Insurance segment is scaling at a brisk 13.4% revenue growth while generating $297 m of free cash flow and delivering a stellar ROE of 32.3%, giving the business a self‑reinforcing cash engine. The Bull Rankings model flags a Quality‑Growth score of 81.8, with Growth as the strongest pillar, confirming that the company’s high‑margin analytics services can keep compounding. The thesis hinges on the ability to sustain this revenue momentum as insurers double‑down on digital transformation.
Moat. EXLS locks in long‑term contracts for claims management, premium administration and actuarial analytics across Insurance and Banking, creating switching costs for large institutional clients who rely on its integrated AI engine. Its 32.3% ROE reflects pricing power derived from category leadership in data‑driven underwriting, a capability that rivals cannot replicate quickly without comparable data assets.
Risk. The market is pricing EXLS at a forward P/E of 22.7, a premium that assumes growth will decelerate to the model‑implied 6% cash‑flow expansion—well below the trailing 13.4% revenue growth, indicating optimism may be overstated. A debt‑to‑equity of 0.57 adds leverage risk if margin pressure emerges, and a beta of 0.84 still leaves the stock vulnerable to broader tech‑service cycles. A sustained slowdown in insurance digitization would trigger the bear case, pulling the stock toward its 52‑week low of $24.85.
Horizon. 1-3 yr $44.63 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $65.34 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $96.92 if current growth sustains into durable earnings power.
14. LRN — Stride, Inc. · score 81
Education & Training Services · price $78.88 · 1Y $90.71 · 5Y $132.81 · 10Y $197.02
FCF $433m C · Rev +4.7% C+ · D/E 0.33 A- · P/E 11.0x A- · PEG 0.43 A
Why now. Stride’s integrated online platform for software engineering and healthcare curricula gives it a cheap, cash‑rich moat that the market is undervaluing. The stock trades at a trailing P/E of 11 and a PEG of 0.43, while generating $433 m of free cash flow and delivering a solid 20.7% ROE—a rare combination in education tech. The thesis rests on the company’s ability to reinvest that cash into buybacks and expand its state‑customized course suite, compounding returns as the platform deepens in schools.
Moat. LRN’s end‑to‑end platform, with single sign‑on and integrated learning‑management, locks K‑12 districts and community colleges into a single ecosystem, creating high switching costs. Its state‑customized curricula let it command premium pricing, which fuels the >20% ROE and sustains cash generation. The platform’s data analytics layer also locks in customers by delivering actionable insights that competitors can’t replicate quickly.
Risk. The reverse‑DCF shows the market pricing in a -12% FCF growth rate in year 1, already slower than the 4.7% revenue growth the business just delivered, implying pessimism about near‑term momentum. If the modest top‑line growth stalls or margins compress, the cheap valuation could evaporate, and the stock could slide toward its 52‑week low of $60.61. A breach of the 52‑week low would confirm the bear case.
Horizon. 1-3 yr $90.71 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $132.81 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $197.02 if current growth sustains into durable earnings power.
15. EPAM — EPAM Systems, Inc. · score 80.2
Information Technology Services · price $109.95 · 1Y $122.82 · 5Y $179.83 · 10Y $266.76
FCF $483m C · Rev +10.8% B · D/E 0.04 A- · P/E 14.9x A- · PEG 0.58 A-
Why now. EPAM’s digital platform engineering franchise is exploding, driven by its cloud‑enabled AI and data services that win large‑scale digital transformation deals. The business is delivering 10.8% revenue growth YoY, a rock‑solid PE of 14.9 that sits well below the sector average, and a free‑cash‑flow generation of $483 m—all while the Bull Rankings model awards an 80.2 quality‑growth score with Value as its strongest pillar and Quality as the softest. The thesis rests on the fact that the market is already pricing a modest 5% cash‑flow growth, well below the 10.8% top‑line pace, leaving upside as the business continues to compound.
Moat. EPAM’s moat lies in its end‑to‑end digital platform engineering platform, which embeds deep integration, migration and automation capabilities that lock in enterprise customers for multi‑year contracts. The high‑margin, recurring nature of these services fuels an ROE of 11.4% and a debt‑to‑equity of just 0.04, creating a low‑cost capital structure that competitors can’t easily replicate without similar scale and expertise.
Risk. The bear case centers on the fact that EPAM’s growth is already decelerating to a modest 5% cash‑flow expansion in the reverse‑DCF, well under the 10.8% revenue growth, suggesting the market may be over‑optimistic about future compounding. A high beta of 1.39 amplifies downside in a volatile tech environment, and any slowdown in cloud‑services demand could compress the 7.2% profit margin. A breach of the 5% cash‑flow growth assumption would trigger a sell‑off and invalidate the bull case.
Horizon. 1-3 yr $122.82 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $179.83 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $266.76 if current growth sustains into durable earnings power.
16. PRDO — Perdoceo Education Corporation · score 80.1
Education & Training Services · price $31.54 · 1Y $36.27 · 5Y $53.10 · 10Y $78.78
FCF $221m C · Rev +11.7% B · D/E 0.11 A · P/E 11.5x A- · PEG 0.65 A-
Why now. The bull case hinges on AIUS’s expanding pipeline of career‑oriented health‑care and business programs that capture rising demand for fast‑track credentials. The business is delivering 11.7% revenue growth YoY, a solid 20.6% profit margin, and generates $221 m of free cash flow while running a modest 0.11 debt‑to‑equity ratio, all at a cheap PE of 11.5x. This combination of high cash conversion and low valuation fuels a compounding engine that should keep earnings accelerating for years to come.
Moat. PRDO’s moat lives in its vertically integrated delivery of online, campus‑based and blended programs across CTU, AIUS and USAHS, which lock students into a single credential pathway and create high switching costs. The strong ROE of 17.1% stems from pricing power in niche professional fields—especially nursing and cybersecurity—where few competitors can match the blended‑learning infrastructure and accreditation breadth PRDO has built.
Risk. The bear case centers on the reverse‑DCF signal that the market is pricing in a -13% FCF growth rate in year 1, far below the trailing 11.7% revenue growth, implying pessimism about enrollment sustainability. A slowdown in AIUS enrollment or a regulatory clamp‑down on for‑profit education could push growth further down, confirming the low‑growth assumption and crushing the valuation thesis.
Horizon. 1-3 yr $36.27 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $53.10 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $78.78 if current growth sustains into durable earnings power.
17. RMD — ResMed Inc. · score 79.4
Medical Instruments & Supplies · price $222.86 · 1Y $250.22 · 5Y $366.35 · 10Y $543.46
FCF $1.6b C+ · Rev +9.9% B · D/E 0.13 B+ · P/E 21.4x B+ · PEG 1.27 B
Why now. ResMed’s AirView cloud platform cements its leadership in the sleep‑and‑breathing health market, driving a 9.9% revenue growth while delivering a 26.9% profit margin and a robust 23.1% ROE. Our Bull Rankings model awards a 79.4/100 quality‑growth score, with Quality as the strongest pillar, underscoring the durability of its high‑margin, data‑rich offering. The thesis rests on the platform’s ability to keep compounding earnings at double‑digit rates as the global sleep‑apnea market expands.
Moat. AirView’s cloud‑connected diagnostics create a sticky data ecosystem for sleep clinics, hospitals and home‑care patients, making switching costly because clinicians rely on longitudinal sleep‑study analytics that only ResMed can aggregate at scale. This high‑switching‑cost environment fuels the 23.1% ROE, reflecting pricing power from category leadership in both the Sleep and Breathing Health segment and the Residential Care Software segment.
Risk. The Bull Rankings model flags Value as the softest pillar, meaning the stock trades at a modest discount to peers (Value 68) but also signals that the market may be pricing in slower growth; the reverse‑DCF shows implied free‑cash‑flow growth of just 5% now, well below the 9.9% trailing revenue growth, suggesting investors are already pessimistic about future compounding. A sustained slowdown in margin or a disruptive home‑diagnostic competitor could push the P/E above the current 21.4, confirming the bear case.
Horizon. 1-3 yr $250.22 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $366.35 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $543.46 if current growth sustains into durable earnings power.
18. CPAY — Corpay, Inc. · score 78.9
Software - Infrastructure · price $401.72 · 1Y $461.00 · 5Y $674.95 · 10Y $1,001
FCF $1.6b C+ · Rev +20.4% A- · D/E 2.75 D · P/E 24.4x B+ · PEG 0.75 A-
Why now. Software - Infrastructure · market cap $26.4b. 6% off the 52-week high of $427.46. Revenue growing +20%, comfortably above the S&P median. PEG 0.75 — paying under fair value for the growth rate. 15 sell-side analysts rate this a Buy with a mean 1-yr target of $461.00 (implying +15% upside).
Moat. Net margin 23% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 32% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 144% of net income — earnings translate cleanly into cash.
Risk. D/E 2.75 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Software — competitive moat is durable until it isn't; watch net revenue retention, gross margin trends, and any new market entrant with a fundamentally lower price point.
Horizon. 1-3 yr $461.00 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $674.95 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $1,001 if current growth sustains into durable earnings power.
19. DXCM — DexCom, Inc. · score 78.8
Medical Devices · price $86.90 · 1Y $95.08 · 5Y $139.21 · 10Y $206.50
FCF $1.4b C+ · Rev +15.5% B+ · D/E 0.53 B · P/E 34.5x C+ · PEG 1.31 B
Why now. The bull case hinges on DexCom’s expanding G7 platform, which is rapidly winning adoption among endocrinologists and patients seeking a seamless CGM experience. The business is delivering 15.5% revenue growth YoY while maintaining a robust 20.1% profit margin and a stellar 38.1% ROE, underscoring the high‑margin, recurring nature of its sensor subscriptions. Our Bull Rankings model awards a Quality‑growth score of 78.8, with Quality as the strongest pillar, confirming that the company’s operational excellence can sustain compounding growth, and the thesis rests on continued G7 market share gains.
Moat. DexCom’s moat stems from its integrated CGM ecosystem—G7 sensors, the Share remote‑monitoring platform, and the Follow app—tied directly to endocrinologists who prescribe the system, creating high switching costs for patients and clinicians alike. The 38.1% ROE reflects pricing power derived from category leadership in continuous glucose monitoring, which competitors can’t replicate quickly due to DexCom’s proprietary sensor technology and FDA‑cleared algorithms.
Risk. The bear case centers on the elevated valuation: a forward P/E of 34.5 implies the market is pricing in growth far above the trailing 15.5% revenue pace, and the reverse‑DCF assumes a 24% FCF growth rate that outstrips historical performance. A slowdown in sensor adoption or pricing pressure could force the P/E down, and with a beta of 1.48 the stock is highly sensitive to market volatility. A miss on the next earnings beat would confirm the over‑optimism and trigger a sell‑off.
Horizon. 1-3 yr $95.08 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $139.21 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $206.50 if current growth sustains into durable earnings power.
20. YUMC — Yum China Holdings, Inc. · score 78.4
Restaurants · price $40.25 · 1Y $61.91 · 5Y $90.65 · 10Y $134.47
FCF $940m C+ · Rev +8.8% B · D/E 0.38 A- · P/E 14.7x B+ · PEG 0.89 B+
Why now. Yum China’s KFC and Pizza Hut franchise network is delivering relentless cash, evidenced by 8.8% revenue growth, a solid 7.8% profit margin, and $940 m of free cash flow over the trailing twelve months. That cash is being funneled into buybacks and dividend hikes, creating a compounding engine that will keep the stock climbing. The thesis rests on the ability of these iconic brands to keep expanding delivery and off‑premise sales in China’s still‑growing quick‑service market.
Moat. The moat lives in the sheer scale of KFC, Pizza Hut and the expanding Taco Bell footprint across China, backed by a proprietary supply chain and digital ordering platform that lock in customers and make it costly for rivals to replicate the same menu‑localization and delivery logistics. The 18.2% ROE reflects pricing power that stems from being the category leader in fast‑food and casual dining in the world’s largest consumer market.
Risk. The stock is priced on a reverse‑DCF that assumes only ~3% free‑cash‑flow growth, well below the 8.8% revenue growth just delivered; any slowdown toward that modest 3% trajectory would crush the upside. A modest profit margin of 7.8% leaves little cushion if input costs rise or competition forces discounting, and a P/E of 14.7, while not lofty, offers limited headroom if earnings falter. A breach of the 3% growth assumption would trigger a sell‑off and invalidate the bull case.
Horizon. 1-3 yr $61.91 (analyst consensus (n=20)) — fundamentals + valuation re-rating. 5 yr $90.65 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $134.47 if current growth sustains into durable earnings power.
21. MU — Micron Technology, Inc. · score 78.1
Semiconductors · price $1063.96 · 1Y $1,522 · 5Y $2,228 · 10Y $3,305
FCF $26.2b A · Rev +167.0% A · D/E 0.04 A- · P/E 14.3x A- · PEG 0.16 A
Why now. Micron’s explosive 167% revenue growth is being driven by its Cloud Memory Business Unit, which is winning massive contracts for high‑bandwidth and CXL‑based memory in hyperscale data centers. Coupled with a 55.9% profit margin and a rock‑solid ROE of 50.1%, the business is compounding cash at a rate that far exceeds typical semiconductor peers. The thesis rests on the continuation of data‑center memory demand, which will keep the growth pillar of our model (91) humming.
Moat. Micron’s moat lives in its deep integration with hyperscale cloud providers through its Core Data Center Business Unit, where customers lock‑in multi‑year supply agreements for HBM and CXL memory that are hard to replace. The 50.1% ROE reflects pricing power derived from being the de‑facto supplier of next‑gen memory for AI workloads, a position competitors can’t duplicate quickly because of Micron’s advanced process nodes and massive wafer capacity.
Risk. The stock’s high beta of 2.23 makes it vulnerable to any tech‑cycle pullback, and the Bull Rankings model’s reverse‑DCF shows the market is already pricing a modest 49% FCF growth in year 1—well below the trailing 167% revenue surge—so any slowdown in data‑center spend would crush the upside. A dip in margin or a missed rollout of the next‑gen memory node would confirm the bear case and knock the price back toward the 52‑week low of $179.61.
Horizon. 1-3 yr $1,522 (analyst consensus (n=46)) — fundamentals + valuation re-rating. 5 yr $2,228 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $3,305 if current growth sustains into durable earnings power.
22. BSX — Boston Scientific Corporation · score 78
Medical Devices · price $42.40 · 1Y $60.79 · 5Y $89.01 · 10Y $132.04
FCF $3.6b B · Rev +13.5% B+ · D/E 0.50 B · P/E 17.2x A- · PEG 0.60 A-
Why now. Boston Scientific’s MedSurg endoscopy franchise is poised to compound revenue at double‑digit rates, anchored by its single‑use duodenoscope and SpyGlass platforms that dominate hospital procurement cycles. The business just delivered 13.5% revenue growth YoY, translates into a robust 17.5% profit margin and generated $3.6 B of free cash flow, all while trading at a modest PE of 17.2x. The Bull Rankings model flags Growth as its strongest pillar (88), meaning the company’s earnings engine is resilient, and the thesis rests on sustained endoscopic adoption driving compounding upside.
Moat. BSX’s MedSurg segment locks in hospitals with proprietary single‑use duodenoscopes and SpyGlass imaging systems that require specialized training and supply contracts, creating high switching costs. This IP‑protected, procedure‑specific hardware underpins a pricing advantage that fuels the 14.7% ROE, far above the sector average, and is not easily replicated by generic competitors.
Risk. The reverse‑DCF shows the market pricing in a sub‑2% FCF growth rate for year 1, well below the 13.5% revenue expansion just reported, implying that any slowdown or margin compression would immediately erode valuation. A modest PE of 17.2x still reflects optimism, and a debt‑to‑equity of 0.5 leaves limited headroom for aggressive buybacks if cash flow falters. A breach of the 52‑week low ($41.94) would confirm that growth is decelerating and the bull case collapses.
Horizon. 1-3 yr $60.79 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $89.01 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $132.04 if current growth sustains into durable earnings power.
23. NFLX — Netflix, Inc. · score 77
Entertainment · price $67.50 · 1Y $92.93 · 5Y $136.05 · 10Y $201.83
FCF $11.2b A- · Rev +16.0% B+ · D/E 0.55 B+ · P/E 21.2x B · PEG 1.15 B+
Why now. Netflix’s global streaming platform is poised to dominate the expanding multi‑language content market, driven by its 28.2% profit margin, 45.3% ROE and 16% revenue growth YoY. The Bull Rankings model rates its Quality at 92, confirming that the business can repeatedly monetize premium subscriptions while funding original series and games. The thesis rests on the ability to compound this high‑margin growth as the subscriber base deepens across devices, delivering outsized returns to shareholders.
Moat. The moat lives in Netflix’s unrivaled content library and seamless delivery across TVs, set‑top boxes and mobiles, creating a high switching cost for members who have built personal watchlists and habit loops. Its 45.3% ROE stems from pricing power as the market leader in subscription entertainment, allowing it to reinvest cash into exclusive titles that competitors cannot replicate quickly.
Risk. The bear case centers on the elevated valuation: a forward P/E of 21.2 and a beta of 1.61 imply the stock is priced for continued rapid growth, yet the reverse‑DCF assumes a 29% FCF growth rate that far exceeds the trailing 16% revenue growth, exposing the upside to any slowdown. A dip in subscriber acquisition or a rise in content costs would push the P/E toward historic norms and could trigger a sell‑off, confirming the risk.
Horizon. 1-3 yr $92.93 (analyst consensus (n=45)) — fundamentals + valuation re-rating. 5 yr $136.05 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $201.83 if current growth sustains into durable earnings power.
24. MELI — MercadoLibre, Inc. · score 76.9
Internet Retail · price $1860.61 · 1Y $2,270 · 5Y $3,323 · 10Y $4,930
FCF $12.4b A- · Rev +46.0% A · D/E 1.69 C+ · P/E 50.6x D · PEG 0.93 B+
Why now. The bull case hinges on Mercado Pago’s expanding financial services moat within the Latin American e‑commerce surge, where the Marketplace‑to‑Payments flywheel fuels relentless compounding. 46% YoY revenue growth demonstrates the platform’s scaling power, while 23.8% ROE proves that capital is being deployed with pricing advantage, and $12.4B of free cash flow gives the balance sheet room to reinvest and outpace rivals. The thesis rests on this virtuous cycle continuing to drive double‑digit top‑line expansion.
Moat. MELI’s moat lives in the integrated Marketplace‑to‑Payments network: sellers and buyers transact on Mercado Libre, then funnel every payment through Mercado Pago, creating a high‑switching‑cost ecosystem. This lock‑in fuels the 23.8% ROE, as the company extracts pricing power from being the dominant fintech conduit in Brazil, Mexico, and Argentina, a position competitors cannot replicate quickly without building a comparable user base.
Risk. The bear case centers on the lofty valuation and slowing growth assumptions: a forward P/E of 50.6 is expensive for a 5.3% profit margin, and the Bull Rankings model’s reverse DCF assumes year‑1 free‑cash‑flow growth of –7%, far below the 46% revenue surge just delivered. Rising leverage (debt‑to‑equity 1.69) and a beta of 1.31 amplify downside if macro‑headwinds hit Latin America, and a break in the Marketplace‑to‑Payments network would immediately crush the growth narrative. A sustained miss on quarterly revenue growth would confirm the bearish view.
Horizon. 1-3 yr $2,270 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $3,323 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $4,930 if current growth sustains into durable earnings power.
25. VEEV — Veeva Systems Inc. · score 76.6
Health Information Services · price $283.45 · 1Y $297.30 · 5Y $435.27 · 10Y $645.70
FCF $1.7b C+ · Rev +16.5% B+ · D/E 0.02 A- · P/E 46.5x C · PEG 1.05 B+
Why now. The Bull Rankings model gives VEEV a 76.6 Quality‑Growth score, with Growth as its strongest pillar, and that strength comes from Veeva’s dominant Vault CRM Suite that locks pharmaceutical and biotech customers into a single cloud platform. The business is delivering 16.5% revenue growth YoY, 29.3% profit margin and $1.7 B of free cash flow, all while trading at a modest 0.02 debt‑to‑equity. The thesis rests on the compounding power of its data‑rich, subscription‑based ecosystem that will keep revenue expanding at double‑digit rates for years to come.
Moat. Veeva’s moat lives in its integrated Commercial Cloud – especially Vault CRM and Veeva OpenData – which create high switching costs for pharma and biotech firms that need consistent, compliant customer reference data across global markets. This lock‑in drives a stable ROE of 13.7% and lets Veeva command pricing power in a niche where regulatory rigor makes home‑grown alternatives impractical.
Risk. The bear case points to the lofty 46.5 P/E, which implies the market is pricing in growth far beyond the trailing 16.5% revenue increase; any slowdown would leave the stock severely overvalued. A modest beta of 0.93 tempers volatility, but the reverse‑DCF shows the price already assumes an 18% FCF growth rate that is barely above current revenue growth – a slip would trigger a sharp re‑rating. A sustained margin compression or a slowdown in new client adoption would confirm the downside.
Horizon. 1-3 yr $297.30 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $435.27 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $645.70 if current growth sustains into durable earnings power.
26. VRT — Vertiv Holdings Co · score 76.5
Electrical Equipment & Parts · price $253.62 · 1Y $337.43 · 5Y $494.03 · 10Y $732.86
FCF $2.9b B · Rev +26.2% A- · D/E 0.70 B · P/E 57.4x D · PEG 0.85 B+
Why now. Vertiv’s dominant position in critical data‑center power and thermal management is fueling a compounding revenue surge of 26.2% YoY, backed by free‑cash‑flow generation of $2.9 B and a staggering ROE of 36.4%. That triple‑digit profitability engine underpins our Bull Rankings model’s Growth pillar (91) and justifies the consensus 1‑yr target of $337.43. The thesis rests on sustained demand for modular UPS and liquid‑cooled thermal solutions as hyperscale operators double‑down on uptime.
Moat. Vertiv’s integrated modular UPS and rack‑level power distribution systems lock in long‑term service contracts with hyperscale cloud providers, creating high switching costs and recurring revenue streams. Its 36.4% ROE reflects pricing power derived from category leadership in AC/DC power management across global data‑center footprints, a capability rivals cannot replicate quickly.
Risk. The stock trades at a lofty P/E of 57.4, far above sector averages, and its beta of 2.05 signals heightened volatility; any slowdown in data‑center capex or a shift to cheaper commodity power solutions would compress margins and expose the valuation premium. A breach of the 52‑week low at $147.82 would confirm the market’s concern that growth is overstated.
Horizon. 1-3 yr $337.43 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $494.03 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $732.86 if current growth sustains into durable earnings power.
27. WMG — Warner Music Group Corp. · score 76.2
Entertainment · price $27.63 · 1Y $37.81 · 5Y $55.36 · 10Y $82.12
FCF $836m C+ · Rev +12.9% B+ · D/E 4.53 D · P/E 22.1x B · PEG 0.48 A
Why now. Entertainment · market cap $14.5b. Down 22% from 52-week high of $35.42 — deep drawdown territory. Revenue growing +13%, comfortably above the S&P median. PEG 0.48 — paying under fair value for the growth rate. 16 sell-side analysts rate this a Buy with a mean 1-yr target of $37.81 (implying +37% upside).
Moat. ROE 79% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 124% of net income — earnings translate cleanly into cash.
Risk. D/E 4.53 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
Horizon. 1-3 yr $37.81 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $55.36 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $82.12 if current growth sustains into durable earnings power.
28. CI — The Cigna Group · score 75.9
Healthcare Plans · price $271.29 · 1Y $342.29 · 5Y $432.14 · 10Y $554.20
FCF $9.1b B+ · Rev +11.3% B · D/E 0.74 C+ · P/E 11.2x A · PEG 0.74 A-
Why now. Healthcare Plans · market cap $71.7b. 13% off the 52-week high of $312.18. Revenue growing +11%, comfortably above the S&P median. PEG 0.74 — paying under fair value for the growth rate. 24 sell-side analysts rate this a Buy with a mean 1-yr target of $342.29 (implying +26% upside).
Moat. ROE 17% is above 15% — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 142% of net income — earnings translate cleanly into cash. $71.7b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk. Net margin 2.3% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Horizon. 1-3 yr $342.29 (analyst consensus (n=24)) — multiple re-rating thesis requires a catalyst. 5 yr $432.14 at ~10% CAGR — dividend compounding plus earnings growth. 10 yr $554.20 if the moat survives secular pressure.
29. CCK — Crown Holdings, Inc. · score 75.4
Packaging & Containers · price $106.58 · 1Y $136.57 · 5Y $199.95 · 10Y $296.62
FCF $1.2b C+ · Rev +10.3% B · D/E 1.86 C+ · P/E 15.3x B+ · PEG 0.64 A-
Why now. Packaging & Containers · market cap $11.6b. 13% off the 52-week high of $122.91. Revenue growing +10%, comfortably above the S&P median. PEG 0.64 — paying under fair value for the growth rate. 14 sell-side analysts rate this a Buy with a mean 1-yr target of $136.57 (implying +28% upside).
Moat. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 153% of net income — earnings translate cleanly into cash.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $136.57 (analyst consensus (n=14)) — fundamentals + valuation re-rating. 5 yr $199.95 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $296.62 if current growth sustains into durable earnings power.
30. SE — Sea Limited · score 75
Internet Retail · price $96.85 · 1Y $155.11 · 5Y $227.10 · 10Y $336.88
FCF $4.5b B · Rev +36.4% A · D/E 0.32 A- · P/E 37.4x D · PEG 0.92 B+
Why now. Our model’s strongest pillar—Growth—means SE’s 36.4% revenue expansion is still accelerating, and the Garena gaming platform is fueling that surge across Southeast Asia. The stock trades at a PE of 37.4 despite a modest 6.9% profit margin, yet the reverse‑DCF shows the market only assumes a 10% FCF growth rate, well below the actual revenue pace, pricing in pessimism and leaving upside for investors who believe the growth engine stays hot.
Moat. Shopee’s mobile‑first marketplace locks in merchants and shoppers with integrated payments and logistics, creating a network effect that rivals can’t replicate quickly, while Garena’s esports ecosystem locks gamers into a single content hub, driving repeat spend and high user stickiness.
Risk. The Bull Rankings model flags diluting shareholders, and the 1.55 beta signals volatility; a PE of 37.4 is lofty for a growth name, and the reverse‑DCF’s 10% implied growth—far slower than the 36.4% revenue climb—suggests the market may be over‑optimistic about future deceleration. A sustained slowdown in Shopee’s GMV or Garena’s user growth would confirm the bear case and crush the upside.
Horizon. 1-3 yr $155.11 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $227.10 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $336.88 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.